cinacalet

Cinacalcet is a synthetic calcimimetic agent that works by mimicking the action of calcium ions in the parathyroid gland, reducing parathyroid hormone (PTH) secretion. It is used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

Cinacalcet was approved by the US FDA in 2004 and has since been used to treat patients with secondary hyperparathyroidism associated with vitamin D deficiency. It works by binding to calcium receptors on the surface of parathyroid gland cells, thereby reducing the secretion of PTH. This reduction in PTH leads to a decrease in bone resorption and the formation of new bone tissue.

Clinical trials have shown that cinacalcet is effective in reducing PTH levels, phosphorus levels, and alkaline phosphatase levels in patients with chronic kidney disease. It has also been associated with a reduction in the risk of cardiovascular events in these patients. Common side effects of cinacalcet include nausea, vomiting, diarrhea, dizziness, and headache. More serious side effects may include hypocalcemia, angina, and myocardial infarction.

Cinacalcet is available in oral tablet form and can be administered either once daily or once weekly. The dosage of cinacalcet is typically determined based on the patient's PTH level, serum calcium level, and phosphorus level. It is essential to closely monitor these parameters in patients undergoing cinacalcet treatment to avoid potential complications such as hypocalcemia.

Overall, cinacalcet has emerged as a valuable treatment option for patients with secondary hyperparathyroidism in chronic kidney disease, offering a range of benefits including improved PTH and phosphorus control, and a reduced risk of cardiovascular events.